구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Taxol |
Overview Company | AstraZeneca |
Overview Modality | CGT |
Overview Target | Non-small Cell Lung Cancer |
Overview Indication | Non-small Cell Lung Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeting epidermal growth factor receptor |
MoA Biomarker | biomarkers TRPM2 and SAMHD1, while upregulating tumor suppressors PRDM1, PCDHGB2, and ICAM1 |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Localization and Biological Activities of Bioflavonoids from Taxus canadensis Marshall.. Relict yew plants ( Taxus L.) are not only ornamental plants with valuable wood but also have the ability to synthesize the unique compound taxol, which is successfully used in the treatment of cancer due to its powerful cytotoxic effect. Due to the presence of taxol, all parts of yew plants are extremely pois… |
Clinical Safety signal | Localization and Biological Activities of Bioflavonoids from Taxus canadensis Marshall.. Relict yew plants ( Taxus L.) are not only ornamental plants with valuable wood but also have the ability to synthesize the unique compound taxol, which is successfully used in the treatment of cancer due to its powerful cytotoxic effect. Due to the presence of taxol, all parts of yew plants are extremely pois… |
Clinical Selected reported efficacy | ORR 36% |
Clinical Reported ORR | 36% |
Clinical Result source | ClinicalTrials.gov NCT00462423 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00462423 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Taxol |
Overview Company | AstraZeneca |
Overview Modality | CGT |
Overview Target | Non-small Cell Lung Cancer |
Overview Indication | Non-small Cell Lung Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeting epidermal growth factor receptor |
MoA Biomarker | biomarkers TRPM2 and SAMHD1, while upregulating tumor suppressors PRDM1, PCDHGB2, and ICAM1 |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Localization and Biological Activities of Bioflavonoids from Taxus canadensis Marshall.. Relict yew plants ( Taxus L.) are not only ornamental plants with valuable wood but also have the ability to synthesize the unique compound taxol, which is successfully used in the treatment of cancer due to its powerful cytotoxic effect. Due to the presence of taxol, all parts of yew plants are extremely pois… |
Clinical Safety signal | Localization and Biological Activities of Bioflavonoids from Taxus canadensis Marshall.. Relict yew plants ( Taxus L.) are not only ornamental plants with valuable wood but also have the ability to synthesize the unique compound taxol, which is successfully used in the treatment of cancer due to its powerful cytotoxic effect. Due to the presence of taxol, all parts of yew plants are extremely pois… |
Clinical Selected reported efficacy | ORR 36% |
Clinical Reported ORR | 36% |
Clinical Result source | ClinicalTrials.gov NCT00462423 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00462423 |
추천 비교
추천 비교